Vertex Pharmaceuticals (VRTX)
NASDAQ: VRTX
· Real-Time Price · USD
403.12
-5.73 (-1.40%)
At close: Oct 03, 2025, 3:59 PM
403.56
0.11%
After-hours: Oct 03, 2025, 07:56 PM EDT
-1.40% (1D)
| Bid | 403 |
| Market Cap | 103.36B |
| Revenue (ttm) | 11.42B |
| Net Income (ttm) | 3.64B |
| EPS (ttm) | 14.06 |
| PE Ratio (ttm) | 28.67 |
| Forward PE | 19.86 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 410 |
| Volume | 1,269,672 |
| Avg. Volume (20D) | 2,043,387.6 |
| Open | 411.67 |
| Previous Close | 408.85 |
| Day's Range | 403.03 - 411.91 |
| 52-Week Range | 362.50 - 519.88 |
| Beta | 0.43 |
| Ex-Dividend Date | n/a |
About VRTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VRTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VRTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsVertex Pharmaceuticals is scheduled to release its earnings on
Nov 3, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+2.85%
Vertex Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
2 months ago
-20.6%
Vertex Pharmaceuticals shares are trading lower following the release of its Q2 financial results. Additionally, the company announced results from its Vx-993 Phase 2 trial. Additionally, several firms cut their respective price targets on the stock.
